New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 30, 2014
07:29 EDTISISIsis Pharmaceuticals price target lowered to $55 from $63 at Stifel
Stifel cut its price target on ISIS after updated P2 ISIS-SMNRx data in Type-1 spinal muscular atrophy showed two patients in the trial experienced an event. The firm is not surprised by this development but believes it reinforces the risk of conducting such trials. Stifel keeps a Buy rating on the shares.
News For ISIS From The Last 14 Days
Check below for free stories on ISIS the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 28, 2014
07:05 EDTISISIsis Pharmaceuticals initiates ISIS-APOCIII Phase 3 study
Subscribe for More Information
August 22, 2014
12:39 EDTISISThese five companies will benefit from increased ALS awareness, MarketWatch says
A recent surge in funding for Lou Gehrig's disease, or ALS, caused by the Ice Bucket challenge that is widespread on social media outlets, will benefit five pharmaceutical companies that are involved in the development of a cure for ALS, according to MarketWatch. The companies that are or have been involved in developing a treatment for ALS include Biogen Idec (BIIB), Avanir Pharmaceuticals (AVNR), Isis Pharmaceuticals (ISIS), Sanofi (SNY), and Bristol-Myers Squibb (BMY), MarketWatch added. Reference Link
August 15, 2014
07:01 EDTISISIsis Pharmaceuticals earns $2M from advancement of ISIS-SMN from Biogen
Isis Pharmaceuticals (ISIS) announced that it has earned a $2M milestone payment from Biogen (BIIB) related to the advancement of the ongoing open-label extension study of ISIS-SMNRx in children with spinal muscular atrophy.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use